The estimated Net Worth of Christopher J Schaber is at least 1.12 百万$ dollars as of 18 May 2022. Dr Schaber owns over 20,000 units of Soligenix Inc stock worth over 309,927$ and over the last 15 years he sold SNGX stock worth over 0$. In addition, he makes 810,303$ as Chairman、 CEO & Pres at Soligenix Inc.
Dr has made over 15 trades of the Soligenix Inc stock since 2009, according to the Form 4 filled with the SEC. Most recently he bought 20,000 units of SNGX stock worth 8,800$ on 18 May 2022.
The largest trade he's ever made was buying 79,051 units of Soligenix Inc stock on 28 September 2009 worth over 19,763$. On average, Dr trades about 5,903 units every 128 days since 2009. As of 18 May 2022 he still owns at least 90,095 units of Soligenix Inc stock.
You can see the complete history of Dr Schaber stock trades at the bottom of the page.
Dr. Christopher J. Schaber Ph.D. is the Chairman, CEO & Pres at Soligenix Inc.
As the Chairman、 CEO & Pres of Soligenix Inc, the total compensation of Dr D at Soligenix Inc is 810,303$. There are no executives at Soligenix Inc getting paid more.
Dr D is 55, he's been the Chairman、 CEO & Pres of Soligenix Inc since . There are 7 older and 5 younger executives at Soligenix Inc. The oldest executive at Soligenix Inc is Richard L. Dunning, 75, who is the Exec. Officer.
Christopher's mailing address filed with the SEC is C/O SOLIGENIX, INC., 29 EMMONS DRIVE, SUITE B-10, PRINCETON, NJ, 08540.
Over the last 15 years, insiders at Soligenix Inc have traded over 502,220$ worth of Soligenix Inc stock and bought 775,279 units worth 1,096,136$ . The most active insiders traders include Randal Jintrexon Corp Kirk、Jerome B Zeldis、Spacavazza Paolo Leadiant B.... On average, Soligenix Inc executives and independent directors trade stock every 115 days with the average trade being worth of 91,349$. The most recent stock trade was executed by Richard Straube on 18 May 2022, trading 8,000 units of SNGX stock currently worth 4,000$.
soligenix, inc. is a late stage biopharmaceutical company committed to developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense. soligenix has two areas of focus: 1) a therapeutics segment dedicated to the development of products for orphan diseases and areas of unmet medical need such as cutaneous t-cell lymphoma, oral mucositis, pediatric crohn's disease, acute radiation enteritis, and 2) a vaccines/biodefense segment to develop vaccines and therapeutics for military and civilian applications in the areas of ricin exposure, anthrax exposure, gastrointestinal acute radiation syndrome, and melioidosis.
Soligenix Inc executives and other stock owners filed with the SEC include: